Barbara Brunnhuber | CEO, Executive in Residence, Mireca & BioPartner
Barbara Brunnhuber is a multi-disciplinary facilitator with an entrepreneurial spirit progressing life sciences ventures. This ability and drive builds on an education in chemistry and economy, applied and advanced during various jobs at the interface of science and business. With a feel for people and processes Barbara spins-out, manages and grows biotech and medtech startups. Currently she wants to bring a mutation agnostic drug to retinal degeneration patients with Mireca. Barbara is supporting LACDR prof. Hankemeier in improving the health system with metabolomics. Together with her colleagues from BioPartner and unlock_ Barbara is opening doors in the Leiden LSH startup scene.
Mireca was set up to continue the R&D work originating from FP7 project DRUGSFORD and to translate the promising data into treatments for patients suffering from rare, inherited retina degeneration. All DRUGSFORD consortium members are founding shareholders of Mireca and in individual cases go back as scientific teams for nearly two decades. Also Mireca's entrepreneurial pedigree in the lineage via its shareholders stands for success and sustainability.
BioPartner supports the growth of startups and scaleups on the Leiden Bio Science Park by renting flexible lab and office spaces and as unlock_ partner.
unlock_ is where LSH startups receive the structure, the program, the network and the instruments they need to turn an idea into a solution.
Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | |
|
© Copyright 2020 by Hyphen Projects